Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results

Dupilumab is used to treat atopic dermatitis (AD) patients who have proven to be refractory to previous treatments. The aim of this study was to assess evolution and patient reported outcome measures in adult patients with moderate-to-severe AD treated with dupilumab in routine clinical practice. Th...

Full description

Bibliographic Details
Main Authors: Servando E. Marron, Lucia Tomas-Aragones, Carlos A. Moncin-Torres, Manuel Gomez-Barrera, Francisco Javier Garcia-Latasa de Aranibar
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Life
Subjects:
atopic dermatitis
patient reported outcome measures
dupilumab
quality of life
satisfaction
efficacy
Online Access:https://www.mdpi.com/2075-1729/11/7/617

Internet

https://www.mdpi.com/2075-1729/11/7/617

Similar Items